Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma-Reference-Cited by-同舟云学术

Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma

Published:2020-10-28 Issue:1 Volume:4 Page:32-35
ISSN:2577-171X
Container-title:IJU Case Reports
language:en
Short-container-title:IJU Case Reports

Author:

Iwaki Takuya¹^ORCID,Niimi Aya¹²³^ORCID,Kano Masato¹,Kurokawa Yoshiaki³,Yoshizaki Uran¹,Nozaki Keina¹,Nomiya Akira¹^ORCID,Miyazaki Hideyo¹,Kume Haruki³

Affiliation:

1. Department of Urology Center Hospital of the National Center for Global Health and MedicineToyama Shinjuku‐ku TokyoJapan

2. Department of Urology New Tokyo HospitalChiba Japan

3. Department of Urology The University of Tokyo Hospital Tokyo Japan

Publisher

Wiley

Subject

Linguistics and Language,Anthropology,History,Language and Linguistics,Cultural Studies

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/iju5.12231

Reference19 articles.

1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

2. Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study

3. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study

4. High incidence of papillary renal cell tumours in patients on chronic haemodialysis

5. OPDIVO (Nivolumab)[package insert]. Bristol‐Myers Squibb New York 2016.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab During Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response;Internal Medicine;2023

2. Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review;Urologia Internationalis;2023

3. Approach to Special Populations with Advanced Renal Cell Carcinoma;Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma;2023

4. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma;CEN Case Reports;2022-11-19

5. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review;Clinical Kidney Journal;2021-05-08